Curis Lifesciences Charts a New Growth Path with Uninova, Export Markets and Branded Pharma Expansion
Curis Lifesciences is expanding its business through a 51% acquisition of Uninova Lifesciences. The strategy focuses on scaling domestic branded pharmaceuticals, increasing exports to Kenya and Nigeria, and launching new injectable products.
Why it matters
This acquisition signals a strategic consolidation in the Indian pharmaceutical sector aimed at diversifying revenue streams and expanding geographic reach.
Ahmedabad, Gujarat, India – Business Wire India
Curis Lifesciences Limited is entering a new phase of growth as it expands across domestic branded pharmaceuticals, international markets and contract manufacturing, with its 51% acquisition of Uninova Lifesciences Pvt. Ltd. adding a new dimension to the company’s evolving business strategy.
The company’s growth roadmap is built around three complementary opportunities — strengthening its merchant export business in Kenya, establishing a long-term pharmaceutical presence in Nigeria, and scaling its domestic branded pharmaceutical business through Uninova. Together, these initiatives are aimed at expanding the company’s product portfolio, geographic presence and revenue base while creating a more diversified business model.
Uninova Strengthens the Domestic Branded Pharma Play
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in